Andreas Lohri
- Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment 44
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 13
- Oncology top 2%
- Viral-associated cancers and disorders 13
- Neurology top 2%
- CNS Lymphoma Diagnosis and Treatment 6
- Hematology top 5%
- Acute Myeloid Leukemia Research 5
-
- Lung Cancer Treatments and Mutations 20
-
- Monoclonal and Polyclonal Antibodies Research 5
- Radiopharmaceutical Chemistry and Applications 4
- Co-authors
- Volker DiehlDirk HasencleverBeate PfistnerF. BoissevainM. SextroSusanne DeckerMarkus SieberPeter E. Müller
- Partner nations
- SwitzerlandGermanyAustria
In The Last Decade
Andreas Lohri
65 papers receiving 2.8k citations
Hit Papers
Peers
Comparison fields: 5 of 85
- Pathology and Forensic Medicine 2.1k
- Genetics 735
- Oncology 1.5k
- Neurology 723
- Hematology 277
Countries citing papers authored by Andreas Lohri
This map shows the geographic impact of Andreas Lohri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Lohri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Lohri more than expected).
Fields of papers citing papers by Andreas Lohri
This network shows the impact of papers produced by Andreas Lohri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Lohri. The network helps show where Andreas Lohri may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Andreas Lohri, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 17 | |
| 2 | 2014 | 37 | |
| 3 | 2013 | 49 | |
| 4 | 2013 | 27 | |
| 5 | 2012 | 60 | |
| 6 | Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab. | 2012 | 7 |
| 7 | 2012 | 25 | |
| 8 | 2011 | 7 | |
| 9 | 2010 | 168 | |
| 10 | 2010 | 18 | |
| 11 | 2009 | 303 | |
| 12 | 2009 | 48 | |
| 13 | 2007 | 29 | |
| 14 | 2005 | 121 | |
| 15 | 2002 | 2 | |
| 16 | 2000 | 7 | |
| 17 | 1997 | 20 | |
| 18 | 1997 | 8 | |
| 19 | 1994 | 65 | |
| 20 | 1994 | 5 |
About Andreas Lohri
Andreas Lohri is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology, having authored 69 papers that have together received 2.8k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (44 papers), Lung Cancer Treatments and Mutations (20 papers), Chronic Lymphocytic Leukemia Research (13 papers), Viral-associated cancers and disorders (13 papers), CNS Lymphoma Diagnosis and Treatment (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Acute Myeloid Leukemia Research (5 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). The work is most often cited by research in Pathology and Forensic Medicine (2.1k citations), Genetics (735 citations) and Oncology (1.5k citations). Andreas Lohri has collaborated with scholars based in Switzerland, Germany and Austria. Frequent co-authors include Volker Diehl, Dirk Hasenclever, Beate Pfistner, F. Boissevain, M. Sextro, Susanne Decker, Markus Sieber, Peter E. Müller, Hartmut Kirchner and Anthony H. Goldstone. Their work appears in journals such as Blood, Annals of Oncology, Swiss Medical Weekly, Journal of Clinical Oncology and International Journal of Radiation Oncology*Biology*Physics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.